

## Eureka Call Austria – Israel 2023

Time schedule	
Announcement of the call	May 2023
Opening of the call	1 June 2023
Deadline for Eureka application	11 September 2023 (12:00 CEST)
Deadline for additional national applications	11 September 2023
Consensus meeting on eligibility	October 2023
National evaluation	October - December 2023
Eureka label procedure and funding decision	December 2023 - March 2024
Project starts	January 2024 – March 2024
Project duration	Up to 24 months

### Eureka Call for R&D projects

FROM 1 June 2023 TO 11 September 2023

Eureka is the world’s biggest public network for international cooperation in R&D and innovation, present in over 45 countries. It is a decentralised intergovernmental organisation aiming to boost the productivity and competitiveness of industries by funding and supporting international collaborative market-driven R&D projects.

This call for projects has been launched following **Eureka’s Network projects framework** based on mutual consent between participating funding bodies from Austria and Israel.

The national funding bodies from **Austria and Israel** have allocated funding for organisations collaborating on international R&D projects.

The partnership will support research and innovation projects within all thematic fields, however the participating countries particularly welcome project applications in the fields of **health and bioconvergence**, with a broad focus on e.g. of immunology, infectious diseases, design and development of vaccines, preventive measures, fast and reliable diagnostics, novel or repurposed therapeutics or prophylactics, personal protective equipment.

You can submit your **Eureka R&D project application** for this call for projects between **1 JUNE 2023 and 11 SEP 2023**. Your project consortium must include organisations based in Austria and Israel. In addition to those partners, partners from other Eureka countries or countries outside of Eureka

can also participate, provided their public funding or self-funding is secured within the call for projects deadlines.

If required by national funding body – which is the case both in Austria and Israel, project participants must also submit **a national funding application**, considering all relevant national procedures, deadlines and submission rules (see section “Funding conditions and rules per national funding body” for detailed information).

## Eureka programme: **Network projects**

### Participating countries/ regions

**Austria, Israel**

### Scope

This call invites consortia to apply high quality R&D projects within all technology fields. However, the participating countries in particular welcome project proposals in the fields of:

Health and Bioconvergence:

- Immunology
- Infectious Disease
- Design and development of vaccines
- Preventive measures
- Fast and reliable diagnostics
- Personal protective equipment
- Novel or repurposed therapeutics or prophylactics
- Other

### Timeframe

- **1 June 2023**: Call opens
- **11 September 2023 (12:00)**: Deadline for Eureka application and national applications in Israel and Austria
- **October 2023**: Eligibility feedback to applicants
- **October 2023**: Consensus meeting of funding agencies
- **October – December 2023**: National evaluation
- **December 2023 – March 2024**: Eureka label procedure and funding decision
- **January 2024 – March 2024**: Project starts
- **Up to 24 months**: Project duration

## Events

The national funding bodies and Eureka Secretariat will organise an information [ONLINE webinar](#) for applicants on **6 June 10:00 CEST**.

In addition, a [b2Match Platform](#) for Austria-Israel Eureka call is at your disposal, whereby a continuous virtual matchmaking of companies and organisations is possible between June and September.

Please contact your national funding body for further information and support. You will find the contacts below in the section “Funding conditions and rules per national funding body”.

## Funding details

- **Austria (FFG - Austrian Research Promotion Agency):** Grant of up to 60% of eligible project costs for small companies, up to 50% of the eligible costs for medium-sized companies or up to 40% of the eligible costs for large companies.
- **Israel (Innovation Israel):** The support is in the form of a conditional grant amounting generally up to 50% (+ regional incentives for companies located in a "development zone") of the eligible R&D budget.

Funding will only be provided to projects that receive a positive evaluation from all relevant national funding bodies. Funding is subject to budgetary availability and national funding conditions outlined by each national funding body.

A Consortium Agreement must be written and signed by project partners, covering project execution, ownership and use of IPR arising from activities and commercialisation of your project’s results. Your Consortium Agreement must abide by the relevant laws of the countries participating in the project.

Unless otherwise specified by all national funding bodies in support of a given project, you must have signed a Consortium Agreement before the start of the project. See section “Funding conditions and rules per national funding body” for exceptions. The Consortium Agreement should include (minimum) the ownership, use of know-how and IPR settlements.

The national funding bodies will fund selected projects. Support will be given to each project partner by their respective national funding body in accordance with national laws, rules, regulations and procedures, on a non-exchange of funds or soft loan basis, and subject to budgetary availability.

If there is no allocated budget for your organisation type in your country and you want to participate in a project consortium, contact your national funding body to see whether there are other funding opportunities available or talk to them about self-funding.

## Eligibility

Eureka has limited eligibility criteria for organisations participating in a **Network projects** consortium:

- Your project idea must represent international cooperation in the form of a specific project.
- The project must be directed at researching or developing an innovative product, process or service with the goal of commercialisation.
- The project must have a civilian purpose.
- Your consortium must include **at least two independent legal entities from a minimum of two Eureka countries (here Austria and Israel)**
- No single organisation or country can be responsible for more **than 70% of the project budget.**

Each participating national funding body may have additional eligibility criteria based on their national regulations. **You are strongly advised, before submitting your application, to contact your national funding body to discuss your project idea and verify your and your project's eligibility.**

This call for projects has additional criteria for organisations to be eligible to receive funding:

- **Austria:** All companies registered in Austria are eligible for funding, universities and research organisations can be funded as subcontractors only.
- **Israel (Innovation Israel):** Eligible partners: Industrial enterprises registered in Israel, with an R&D capabilities. (Universities and RTOs only as Sub-contractors to Israeli companies)

For detailed information on other national rules please see section “Funding conditions and rules per national funding body”.

## Evaluation

Your project application will be reviewed according to our Network projects evaluation methodology.

### 1. Impact

- Is the market properly addressed (i.e. size, access and risks)?
- Is the value creation properly addressed (i.e. employment opportunities and environmental and societal benefits)?
- What are the competitive advantages of your project (i.e. strategic importance, enhanced capabilities and visibility)?
- Are your commercialisation plans clear and realistic (i.e. return on investment, geographical and sectoral impact)?

### 2. Excellence

- What is the degree of innovation? (i.e. is the proposed product, process or service state-of-the-art? Is there sufficient technological maturity and risk)?
- How is the new knowledge going to be used?
- Is your project scientifically and technically challenging for consortium partners?
- Is the technical achievability and risk properly addressed?

### 3. Quality and efficiency of implementation

- What is the quality of your consortium (i.e. balance of the partnership and technological, managerial and financial capabilities of each partner)?
- Is there added value through international cooperation?
- Is your project management and planning realistic and clearly defined (i.e. methodology, planning approach, milestones and deliverables)?
- Is your cost structure reasonable (i.e. costs and financial commitment for each consortium partner)?

### 4. Overall perception

Experts will list three positive and negative points to your application and finally state whether they recommend your project for public investment.

Your national funding body may carry out a further evaluation (performed by the national project coordinator and technical experts) according to national rules before allocating funds to successful applicants.

### Country evaluation

Your project application will be reviewed according to the following additional national evaluation processes:

- **Austria:** The evaluation of the Austrian project part is carried out by internal experts at FFG.
- **Israel:** Evaluation will be done by the evaluators of the Innovation Authority.

## Applying

1. **Contact your national funding body** to discuss your project idea, financial viability, eligibility and national procedures.
2. **Create an account** on our application portal (one per consortium) [https://eureka.smartsimple.ie/s\\_Login.jsp](https://eureka.smartsimple.ie/s_Login.jsp) and select the funding opportunity you want to apply to.
3. Using the portal, complete **one application form per consortium** (in English) and invite other consortium partners to fill in a partner form.
4. Your project application must be completed online by **11 September 2023 12:00 CEST**.
5. Upload a GANTT chart (one per consortium), a signed and completed co-signature form (which you can download from the platform) and any additional required annexes.
6. Your application will be checked for completeness and eligibility before being reviewed using a standard evaluation procedure. If successful, your project will receive a Eureka label.

7. If required by your national funding body, you must **submit a related national funding application** – taking into account all relevant national procedures and submission rules. Submission deadlines might differ between the participating national funding bodies.
8. Your national funding body may carry out a further evaluation (performed by the National Project Coordinator and technical experts) according to national rules before allocating funds to successful applicants.
9. The final step is to complete and sign a consortium agreement (CA). We recommend that you seek legal advice when drafting your CA.

## Funding conditions and rules per national funding body and contacts

Austria			
<b>Topics of Interest</b>	All thematic fields however specific thematic focus is on health and bioconvergence with a broad focus on e.g. immunology and infectious diseases, design and development of vaccines, preventive measures, fast and reliable diagnostics, novel or repurposed therapeutics or prophylactics and personal protective equipment.		
<b>Timeline</b>	1 June – 11 September 2023		
<b>Budget</b>	2 Mio €		
<b>Specific National rules</b>	In addition to the international Eureka application, the companies must also submit a national funding application to the FFG under <a href="#">Austrian Life Sciences Programme 2023</a> (if your project is focusing health and topics recommended above). Further information is available here: <a href="https://www.ffg.at/europa/ausschreibungen/eureka-israel-2023">https://www.ffg.at/europa/ausschreibungen/eureka-israel-2023</a> Project applications must be submitted online via FFG eCall: <a href="https://ecall.ffg.at">https://ecall.ffg.at</a> (under Austrian Life Sciences Programme 2023). Joining a project on self-funded basis is possible; project application on other topics is possible – in both cases, please contact the Eureka NPC at FFG.		
<b>Eligible costs and funding rates</b>	All companies registered in Austria are eligible for funding, universities and research organisations can be funded as subcontractors only. The evaluation of the Austrian project part is carried out by internal experts at FFG. The project must fulfil the national criteria. Funding in Austria under Austrian Life Sciences Programme 2023 is provided for the max duration of 2 years. General Programme provides grants for Austrian SMEs participating in Eureka projects: <ul style="list-style-type: none"> <li>- Up to 60% of the eligible costs for small companies</li> <li>- Up to 50% of the eligible costs for medium-sized companies</li> <li>- Up to 40% of the eligible costs for large companies</li> </ul>		
<b>Additional documents required</b>	National full project proposal		
<b>Contact persons</b>	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> Ines Marinkovic  Eureka NPC  Email: <a href="mailto:ines.marinkovic@ffg.at">ines.marinkovic@ffg.at</a>  Tel: +43 57755-4906 </td> <td style="width: 50%; vertical-align: top;"> Michael Walch  Eureka NPC  Email: <a href="mailto:Michael.walch@ffg.at">Michael.walch@ffg.at</a>  Tel: +43 57755-4901 </td> </tr> </table>	Ines Marinkovic Eureka NPC Email: <a href="mailto:ines.marinkovic@ffg.at">ines.marinkovic@ffg.at</a> Tel: +43 57755-4906	Michael Walch Eureka NPC Email: <a href="mailto:Michael.walch@ffg.at">Michael.walch@ffg.at</a> Tel: +43 57755-4901
Ines Marinkovic Eureka NPC Email: <a href="mailto:ines.marinkovic@ffg.at">ines.marinkovic@ffg.at</a> Tel: +43 57755-4906	Michael Walch Eureka NPC Email: <a href="mailto:Michael.walch@ffg.at">Michael.walch@ffg.at</a> Tel: +43 57755-4901		

Israel	
<b>Topics of Interest</b>	All thematic fields however specific thematic focus is on Health and Bioconvergence with a broad focus on e.g. immunology and infectious diseases, design and development of vaccines, preventive measures, fast and reliable diagnostics, novel or repurposed therapeutics or prophylactics and personal protective equipment.
<b>Timeline</b>	1 June – 11 September 2023
<b>Budget</b>	2 Mio €
<b>Specific National rules</b>	Eligible partners: Industrial enterprises registered in Israel, with an R&D capabilities. (Universities and RTOs only as Sub-contractors to Israeli companies)
<b>Eligible costs and funding rates</b>	<p>The support is in the form of a conditional grant amounting generally up to 50% (+ regional incentives for companies located in a "development zone") of the eligible R&amp;D budget.</p> <p>When a project results in sales of a product, service or process, the financial support must be repaid to the Israel Innovation Authority according to its regulations (in general, royalties are paid at rates beginning at 3% of sales, depending on various criteria. Royalties are payable until 100% of the amount of the grant has been repaid with interest as provided in the applicable regulations).</p> <p>For further information regarding funding mechanisms of IIA see here: <a href="https://innovationisrael.org.il/node/4698/rules">https://innovationisrael.org.il/node/4698/rules</a></p>
<b>Additional documents required</b>	Israeli applicants have to submit to the Innovation Authority as described here <a href="https://innovationisrael.org.il/international/rnd/bilateral">https://innovationisrael.org.il/international/rnd/bilateral</a>
<b>Contact persons</b>	Mr. Uzi Bar-Sadeh, Tel: +972-3-5118185, E-mail: <a href="mailto:uzi@iserd.org.il">uzi@iserd.org.il</a>